EF Hutton Reiterates Hold on GT Biopharma, Maintains $2 Price Target
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Tony Butler has reiterated a 'Hold' rating on GT Biopharma (NASDAQ:GTBP) and maintained a $2 price target.
August 07, 2023 | 4:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
EF Hutton has reiterated a 'Hold' rating on GT Biopharma and maintained a $2 price target.
The reiteration of the 'Hold' rating and maintenance of the $2 price target by EF Hutton indicates that the analyst believes the stock is fairly valued at its current price. This could potentially limit any significant short-term price movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100